“We have very few devices that have proven effective so far,” WHO’s Assistant Director General for Access to Medicines, Vaccines and Pharmaceuticals, Mariangela Simao, said this week.
However, she is hopeful that several large-scale ongoing trials of potential therapy will bring good news by the end of the year.
Researchers are in the process of testing on about 330 drugs, of which about 150 are already being tested on people, Research research as per policy, A global health think tank. Of those, about 60 are in late stages of testing.
Promise – and drawbacks – of biotherapy
In the most optimistic scenario, a pair of so-called monoclonal antibodies, which can both prevent people from having Kovid-19 and cure the disease, will be released at the end of the year, said Nick Chapman, CEO of policy treatment research, told Politico. Can be approved up to.
U.S. National Institutes of Health Describes these antibodies as laboratory-produced versions of proteins produced naturally by the immune system in response to viruses or other pathogens. “Monoclonal antibodies may provide short-term protection from SARS-COV-2 and serve as important components of the Kovid-19 pandemic response,” the NIH stated.
drugmakers Eli Lilly; Regeneron And Roche; And CSL Behring And Takeda is working on a few companies, according to Chapman and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
According to him, there are some 70 under development for the treatment and prevention of Kovid-19 Non-profit scientific organization IAVI. He is already used to treat a wide variety of cancers and autoimmune disorders, over 100 licensed in the last 30 years, Report good Released in August by IAVI and the Global Health Foundation Welcome.
Chapman stated that these are the most promising class of so-called biotherapy drugs that actually give rise to viruses. But they also have drawbacks.
Most of them are injectables, which also challenges them to test – people don’t like to get shots, Simao of WHO said.
Increasing production to make millions of doses of bioparties will also be a major challenge, as the developing world has limited capacity for that kind of manufacturing, WHO chief scientist Soumya Swaminathan said this week.
Finally, they are much more expensive than regular drugs, Chapman said, which could dramatically limit their potential effects.
Expected and dashed expectations
“Most likely, there will not be an effective treatment, not a magic bullet to deal with the Kovid-19,” IFPMA Director General Thomas Cuney told reporters in early September.
“We will need different treatments for different patient groups for different stages of the disease,” he said.
In addition to antibody therapy, the industry is also working on antivirals and drugs with anti-inflammatory effects to treat people with Kovid-19 with QI.
Gilead’s Remedisvir, which received emergency use authorization from the US Food and Drug Administration in the spring and conditional marketing from the European Medical Agency in the summer, is part of the antiviral category. A large study conducted by the NIH showed that it helps hospitalized people who are seriously ill and recover more quickly. Earlier this month, the FDA also allowed it to be used in other groups of hospitalized patients who are less ill. But it is not yet clear whether it prevents deaths.
Gilead CEO Daniel O’Day said the drug is still being tested in some 36 clinical trials. Among other things, they are looking to assess whether it works better in fighting coronoviruses in combination with other drugs – for example, in a cocktail similar to the combination of drugs to treat people with HIV. The company is also testing whether the drug works inside rather than being injected, as is the case now, to make administration easier.
However, Remedisvir will not work as a pill, due to the way it is metabolized in the body. ODD said Gilead has not been able to meet the global demand for the drug so far, but it is expected in October.
Chapman of Policy Cure Research stated that it is important to develop a pill form of treatment of coronovirus to ensure widespread use.
A pilot drug code-name EIDD-2801, Which is being developed by Ridgeback Biotherapeutics and Merck & Co., may be the pill. The drug inhibits replication of many RNA viruses, including SARS-CoV-2, Ridgeback said. In animal studies of coronaviruses that cause SARS and MERS, the drug has been shown to improve pulmonary function, decrease body weight, and reduce the amount of virus in the lungs.
In early September, WHO recommended The use of so-called corticosteroids for the treatment of inflammation caused by coronovirus in people with severe or severe conditions. Dexamethasone, which was found to be effective in people receiving breathing aid, is an example. These inexpensive medicines have long been used to treat other conditions such as asthma, allergies, lupus and rheumatoid arthritis.
Politicians have raised high expectations for treatments to fight coronovirus, but some of the most prevalent therapies have also become the largest. The most notorious: the drug hydroxychloroquine, which has been heavily promoted by US President Donald Trump, among others.
FDA granted hydroxychloroquine only an emergency use authorization back it up A few months later, after a clinical trial in hospitalized patients, there was no benefit from decreased likelihood of death or rapid recovery from the drug. Conversely, it can lead to serious health issues such as heart rhythm problems and blood disorders, the FDA warned.
In Japan, outgoing Prime Minister Shinzo Abe Place your bet on a drug For the treatment of influenza, it is sold under the brand name of Avigan. Testing of effects of coronovirus of Avigan is expected to be completed in Japan this month Media reports, Although an interim report in May was not promising.
Cuie, from the global drug lobby IFPMA, said the industry has come a long way since the onset of the epidemic, “but we have to honestly admit that some expectations were dashed. Some expectations were met, and more is expected to come.
A transformational therapy is needed to fight the virus, said Chapman from Policy Cure Research. He said that it is expected that some people will be coming later.
Determination on existing drugs as a treatment for potential viruses, rather than the more promising drugs in the earlier stages of development, “turned things back on course,” he said.
COVID Vaccine Race Latest
AstraZeneca vaccine test break: The way America was daring to save Trump, which had not yet been proven safe and effective, testing for one of the most advanced candidate vaccines Was stopped Due to security concerns. One participant in the clinical trial became ill, and a team is now investigating whether the vaccine was caused. AstraZeneca CEO Pascal Soriot Said on thursday Pauses were not uncommon in such tests. He did not confirm media reports that the participant had come down with transverse myelitis, an inflammatory disease that affects the spinal cord. If the company can resume testing soon, it should be known before the end of the year whether the vaccine works to protect people against coronovirus infection, he said.
Vaccines need to prove more than efficacy to effectively fight the epidemic: Of the eight front-running vaccine candidates, only one – manufactured by China’s casinos – requires a single dose for complete immunization, the Policy Cure Research says New analysis. And at least three of them – are being developed by the modern; Pfizer / BioNTech; And AstraZeneca and Oxford University – minimum product stability and The storage criteria set by WHO, According to the analysis. The think tank states that “for wider public health impact, and effectively mitigating the COVID-19 pandemic, a vaccine will be needed that is appropriate in a variety of contexts, including resource-limited settings and different age groups.”
Vaccine confidence before the epidemic: Distrust and outright opposition to vaccination have long been an issue, and current debates surrounding future coronavirus vaccines may make matters worse. a new report Published on Thursday, where the world relied on vaccines before the virus.
Between November 2015 and December 2019, “the importance, safety, and effectiveness of vaccines fell in Afghanistan, Indonesia, Pakistan, the Philippines, and South Korea,” the report, led by Professor Heidi Larson of the infectious department, says. In Disease Epidemiology London School of Hygiene and Tropical Medicine. She is also the founding director of the Vaccine Confidence Project. There were indications that confidence in some EU countries such as Finland, France, Ireland and Italy has improved between 2018 and 2019, “with recent losses in Poland.”
Global Health Snapshot
North America: Excerpts from Trump’s February interview with veteran journalist Bob Woodward have dominated the news cycle in the country due to the US president’s admission that he was playing with the virus knowing it was more deadly than the flu. But some health journalists on Twitter Is also raised Trump said that the WHO has protested over the past few months: the virus is airborne, and thus spreads not only during contact between an infected person and a healthy person.
Latin America: Robot Relieves loneliness Of Mexican coronavirus patients.
Asia: India Reported a new record spike Some 95,000 cases of coronovirus infection a day. As of September 10, about 4.4 million – in some cases, the country, ranked second in the world after the US, has overtaken Brazil.
Europe: Teacher in a Bosnian Village Build an open-air classroom To protect children from Kovid-19.
Middle East: Community transmission of coronaviruses is widespread in war-torn Syria The United Nations says.
Africa: Nigerian Resident Doctor Postpone their strike To allow the government to deal with their demands for better pay and working conditions amid the epidemic.
Oceania: In people New zealand Experiencing more depression and anxietySince the Y Coronovirus lockdown, the country is being seen as a success story in the global fight against the epidemic.
Global: Kovid-19 can reverse decades of progress towards ending preventive child deaths, UN agencies warned.